Monopar Therapeutics Inc. (MNPR)

NASDAQ: MNPR · IEX Real-Time Price · USD
0.822
-0.178 (-17.79%)
Feb 29, 2024, 3:51 PM EST - Market closed
-17.79%
Market Cap 14.87M
Revenue (ttm) n/a
Net Income (ttm) -9.48M
Shares Out 14.87M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,298,422
Open 0.970
Previous Close 1.000
Day's Range 0.702 - 1.050
52-Week Range 0.274 - 3.110
Beta 0.82
Analysts Strong Buy
Price Target 17.00 (+1,948.19%)
Earnings Date Mar 21, 2024

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2019
Employees 11
Stock Exchange NASDAQ
Ticker Symbol MNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 1,948.19% from the latest price.

Price Target
$17.0
(1,948.19% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

2 days ago - GlobeNewsWire

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

9 days ago - GlobeNewsWire

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual Meet...

4 months ago - GlobeNewsWire

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

4 months ago - GlobeNewsWire

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

5 months ago - GlobeNewsWire

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Camsirubicin Phase 1b Trial Currently at 5th Dose­-Level (650 mg/m 2), Generating Encouraging Results MNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies

7 months ago - GlobeNewsWire

Monopar to Participate in the Radiopharma Forum by the Lake 2023

WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

9 months ago - GlobeNewsWire

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...

9 months ago - GlobeNewsWire

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

Camsirubicin Phase 1b Dose­Escalation Trial Enrolling 5th Dose­Level Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results Camsirubicin Phase 1b Dose­Escala...

10 months ago - GlobeNewsWire

Monopar to Present at the Jefferies Radiopharma Innovation Summit

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

1 year ago - GlobeNewsWire

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

1 year ago - GlobeNewsWire

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Validive ® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m 2)

1 year ago - GlobeNewsWire

Monopar to Present at the 35th Annual Roth Conference

WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

1 year ago - GlobeNewsWire

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an...

1 year ago - GlobeNewsWire

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...

1 year ago - GlobeNewsWire

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Preclinical Data at ASH 2022 in December

1 year ago - GlobeNewsWire

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend...

1 year ago - GlobeNewsWire

Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients

Shares of Monopar Therapeutics Inc. MNPR, +6.92% gained 13.5% in premarket trading on Wednesday after the company said it completed enrollment in a Phase 2b clinical trial evaluating its experimental ...

1 year ago - Market Watch

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis

Interim Analysis Planned for Q1 2023 Interim Analysis Planned for Q1 2023

1 year ago - GlobeNewsWire

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exten...

1 year ago - GlobeNewsWire